


**MATERIALS LICENSE**

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee 1. DMS Health Technologies  2. 109 South Petro Avenue Sioux Falls, SD 57107		In accordance with letter dated April 13, 2022.	4. Expiration Date: April 30, 2022
		3. License No.: 40-32477-01 is amended in its entirety to read as follows:	5. Docket No.: 030-36404 Reference No.:
6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license	9. Authorized use
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As Needed	A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100.
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As Needed	B. For use in imaging and localization studies permitted by 10 CFR 35.200.
C. Any byproduct material permitted by 10 CFR 31.11	C. Prepackaged Kits	C. 30 millicuries total	C. In vitro studies.
D. Cesium-137	D. Sealed Sources (QSA Global, Inc., Model 77302)	D. 200 millicuries per source and 200 millicuries total	D. For storage only.



**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License No.: 40-32477-01

Docket or Reference No.:  
030-36404

Amendment No. 56

**CONDITIONS**

10. Licensed material may be received, stored, and dispatched from the licensee's facilities located at:

A. 109 South Petro Avenue, Sioux Falls, South Dakota, 57107

B. 305 7th Avenue SE, Watertown, South Dakota, 57201

C. Licensed material may be received by licensee personnel only, used, and stored at the following fixed facility located at 109 South Petro Avenue, Sioux Falls, South Dakota, 57107.

D. Licensed material (excluding Item 6.D.) may be received, stored and used at temporary job sites anywhere in the United States where the U.S. Nuclear Regulatory Commission maintains jurisdiction for regulating the use of licensed material, including areas of exclusive Federal jurisdiction within Agreement States.

If the jurisdiction status of a Federal facility within an Agreement State is unknown, the licensee should contact the federal agency controlling the job site in question to determine whether the proposed job site is an area of exclusive Federal jurisdiction. Authorization for use of radioactive materials at job sites in Agreement States not under exclusive Federal jurisdiction shall be obtained from the appropriate state regulatory agency.

11. The Radiation Safety Officer (RSO) for this license is Nathan Dykstra, CNMT.

12. Licensed material shall only be used by, or under the supervision of:

A. Individuals permitted to work as authorized users or authorized nuclear pharmacists in accordance with 10 CFR 35.13 and 10 CFR 35.14.

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**


License No.: 40-32477-01

Docket or Reference No.:  
030-36404

Amendment No. 56

B. The following individuals are authorized users for the material and medical uses as indicated:

<u>Authorized User (M.D., D.O., etc.)</u>	<u>Material and Use</u>
James R. Bergh, M.D.	35.100; 35.200
Alfred P. Caccaro, M.D.	35.100; 35.200
Joseph Caresio, M.D.	35.100; 35.200
Kevin Casper, M.D.	35.100; 35.200
Patrick Conte, M.D.	35.100; 35.200
John Dymond, M.D.	35.100; 35.200
Michael E. Farber, M.D.	35.100; 35.200
Christopher D. Fischer, M.D.	35.100; 35.200; 31.11
Daniel R. Fritz, M.D.	35.100; 35.200
Michael P. Green, D.O.	35.100; 35.200
Christopher Gregory, M.D.	35.100; 35.200
Barry A. Gubin, M.D.	35.100; 35.200
Thomas S. Helling, Jr., M.D.	35.100; 35.200
Rafe Heng, M.D.	35.100; 35.200
Nathaniel R. Jewell, M.D.	35.100; 35.200
Orvar T. Jonsson, M.D.	35.200
Andrew Keenan, M.D.	35.100; 35.200
Christine Keesling, M.D.	35.100; 35.200
Kenneth L. Koontz, M.D.	35.100; 35.200
Steven Krause, D.O.	35.100; 35.200
Leslie H. Lenter, M.D.	35.100; 35.200
Richard M. Levey, M.D.	35.100; 35.200



**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**


License No.: 40-32477-01

Docket or Reference No.:  
030-36404

Amendment No. 56

Authorized User (M.D., D.O., etc.)Material and Use

Aaron M. Lewis, M.D.	35.100; 35.200
Kevin L. Litwin, M.D.	35.100; 35.200
Fred Clinton Lovrien, M.D.	35.100; 35.200; 31.11
Robert A. MacNaughton II, M.D.	35.100; 35.200
Steven L. Martin, M.D.	35.200
Barry Scott Monfore, M.D.	35.100; 35.200
Omar Nass, M.D.	35.200
Randall C. Newth, M.D.	35.100; 35.200
Robert C. Newth, M.D.	35.100; 35.200
Patrick M. O'Toole, M.D.	35.100; 35.200
Brad Alan Paulson, M.D.	35.100; 35.200
Stephen R. Peters, M.D.	35.100; 35.200
Marian S. Petrasko, M.D.	35.200
John Brian Pope, M.D.	35.100; 35.200
Thomas J. Posch, M.D.	35.100; 35.200; 31.11
Timothy G. Raveill, M.D.	35.100; 35.200
Dean K. Rigby, M.D.	35.100; 35.200
Larry S. Sidaway, M.D.	35.100; 35.200
Adam T. Stys, M.D.	35.100; 35.200
Tomasz P. Stys, M.D.	35.100; 35.200
David A. Swanson, M.D.	35.100; 35.200
Arliss N. Thompson, M.D.	35.100; 35.200; 31.11
Mario Todorov, M.D.	35.100; 35.200
Michael Joseph Vierra, M.D.	35.100; 35.200



**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License No.: 40-32477-01

Docket or Reference No.:

030-36404

Amendment No. 56

Authorized User (M.D., D.O., etc.)Material and Use

Vijay Viswanathan, M.D.

35.100; 35.200

Anthony Lee Wheeler, M.D.

35.200

Paul M. Williams, D.O.

35.100; 35.200

Frank Yuppa, M.D.

35.100; 35.200

13. For sealed sources not associated with 10 CFR Part 35 use, the following conditions apply:

- A. Sealed sources and detector cells shall be tested for leakage and/or contamination at intervals not to exceed the intervals specified in the certificate of registration issued by the U.S. Nuclear Regulatory Commission under 10 CFR 32.210 or by an Agreement State. In the absence of a registration certificate, sealed sources shall be tested for leakage and/or contamination at intervals not to exceed 6 months, or at such other intervals as specified.
- B. Notwithstanding Paragraph A of this Condition, sealed sources designed to primarily emit alpha particles shall be tested for leakage and/or contamination at intervals not to exceed 3 months.
- C. In the absence of a certificate from a transferor indicating that a leak test has been made within the intervals specified in the certificate of registration issued by the U.S. Nuclear Regulatory Commission under 10 CFR 32.210 or by an Agreement State, prior to the transfer, a sealed source received from another person shall not be put into use until tested and the test results received.
- D. Sealed sources need not be tested if they contain only hydrogen 3; or they contain only a radioactive gas; or the half-life of the isotope is 30 days or less; or they contain not more than 100 microcuries of beta- and/or gamma-emitting material or not more than 10 microcuries of alpha emitting material.
- E. Sealed sources need not be tested if they are in storage and are not being used; however, when they are removed from storage for use or transferred to another person and have not been tested within the required leak test interval, they shall be tested before use or transfer. No sealed source shall be stored for a period of more than 10 years without being tested for leakage and/or contamination.

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License No.: 40-32477-01

Docket or Reference No.:  
030-36404

Amendment No. 56

- F. The leak test shall be capable of detecting the presence of 185 Becquerels (0.005 microcuries) of radioactive material on the test sample. If the test reveals the presence of 185 Becquerel (0.005 microcuries) or more of removable contamination, a report shall be filed with the U.S. Nuclear Regulatory Commission in accordance with 10 CFR 30.50(c)(2), and the source shall be removed immediately from service and decontaminated, repaired, or disposed of in accordance with Commission regulations.
- G. Tests for leakage and/or contamination, including leak test sample collection and analysis, shall be performed by the licensee or other persons specifically licensed by the U.S. Nuclear Regulatory Commission or an Agreement State to perform such services.
- H. Records of leak test results shall be kept in units of becquerels (microcuries) and shall be maintained for 3 years.
14. Sealed sources containing licensed material shall not be opened or sources removed from source holders by the licensee, except as specifically authorized.
15. The licensee shall conduct a physical inventory every 6 months, or at other intervals approved by the U.S. Nuclear Regulatory Commission, to account for all sealed sources and/or devices received and possessed under the license. Records of inventories shall be maintained for 3 years from the date of each inventory, and shall include the radionuclides, quantities, manufacturer's name and model numbers, and the date of the inventory.

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License No.: 40-32477-01

Docket or Reference No.:  
030-36404

Amendment No. 56

16. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

A. Application dated October 12, 2011 (ML11300A262)

B. Letter dated February 7, 2012 (ML12058A526)


C. Letter dated April 10, 2012 (ML12109A197)

D. Letter dated November 19, 2012 (ML12338A226)

E. Letter dated October 14, 2015 (ML15313A502)

F. Letter dated March 21, 2017 with enclosures (ML17088A804)

G. Letter dated November 12, 2020 (ML20321A201), letter dated November 18, 2020 with enclosures (ML20325A106) and letter dated November 20, 2020 with enclosures (ML20325A304)



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: July 11, 2022

By: \_\_\_\_\_

Latischa M. Hanson  
Region IV